AS

Abhishek Shyam Wai

Active Director Additional Director DIN 08685363
DIN 08685363 First appointment Jan 2020 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Abhishek Shyam Wai

Data last updated:

Abhishek Shyam Wai is an Additional Director at Medeasy Pharma Private Limited (since 2020). The company operates in Chemicals.

DIN 08685363
Primary Designation Additional Director
Industry Chemicals
First Appointment 30 Jan 2020
Oldest Company Age 6 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Medeasy Pharma Private Limited U24230PN2020PTC188966
Additional Director30 Jan 20202020Active

Board colleagues of Abhishek Shyam Wai

Directorship timeline

Open interactive timeline →
Medeasy Pharma Private Limited
Premium access

Shareholding and investment profile for Abhishek Shyam Wai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abhishek Shyam Wai

Abhishek Shyam Wai currently holds 1 directorship: Medeasy Pharma Private Limited (Additional Director, since 30 Jan 2020).

Abhishek Shyam Wai was first appointed on 30 Jan 2020 as Additional Director at Medeasy Pharma Private Limited.

The current boards of Abhishek Shyam Wai's companies include Dnyaneshwar Eknath Pathare (Medeasy Pharma Private Limited), Ramesh Shivram Satpute (Medeasy Pharma Private Limited), Vikram Ramesh Satpute (Medeasy Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available